1Carter P. Improving the efficacy of antibody-based cancer therapies[J]. Nat Rev Cancer,2001,2(11): 118-129.
2Ishida T,Tmai K. The expression technology of chimeric and humanized antibodies [J]. Nippon Rinsho, 2002, 60 (3): 439-444.
3Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting[J]. J Immunol Methods, 2001,1 (2) : 47-66.
4Koelemijr,Kuppen PJK, Van de velde CJH,et al. Bispecific antibodies recruiting myeloid effector cells for tumor therapy [J]. Critical Reviews in Oncology/Hematalogy,2001,38 : 47-61.
5Girand A, Ataman OY, Battail N, et al. Generation of monoclonal antibodies to mative human imminodeficiency virus type Ⅰ envelope gly coprtein by immunization of mice with naked RNA [J]. J Virol Methodes, 1999,79 ( 1 ) : 75-84.
6Wiseman GA, Leigh B, Erwin WD, et al. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab - refractory non - Hodgkin lymphoma [J]. Cancer,2002,94 (2) : 1349-1357.
7Leong SR,DeForge L,Presta L,et al. Adapting pharmacokinetic properties of a humanized anti- interleukin-8 antibody for therapeutic applications using site-specific pegylation [J]. Cytokine, 2001,16 (11 ) : 106-119.
9Newton DL, Ryback SM . Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA[J]. Expert Opin Biol Ther, 2001,6 (11): 995-1003.
10Shi N, Boado RJ, Pardridge WM. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes[J]. Pharm.Res, 2001,18(4) :1091-1095.
